Morvus Technology

Morvus Technology is a privately owned pharmaceutical company engaged in the discovery, development, and out-licensing of novel oncology drugs and platform technologies.

The company's portfolio includes ProTide nucleoside chemistry, out-licensed to NuCana plc for clinical development; an inhaled anti-tumour agent for lung cancer in development through subsidiary Gordian Pharma; and a Clostridioides difficile vaccine platform out-licensed to a major pharmaceutical partner.